Cell MedX Corp. (CMXC) Announces Results of Preliminary Analysis of Metabolomic Assays in Phase 1 Pilot Clinical Trial
LAS VEGAS, NV — (Marketwired) — 02/25/15 — Cell MedX Corp. (OTCQB: CMXC) (the "Company") is pleased to announce that it has received the first results of the analysis of metabolomic assays taken during the Phase 1 pilot clinical trial.The pilot clinical discovery phase trial in two diabetic subjects was performed in January 2015. Its main objective was to examine the short term metabolic impact of a single treatment with e-balance technology. Additional assays are pending. Analysis